1
|
Abstract
Despite widespread efforts to reduce the need for homologous blood transfusion during and after cardiac surgery, most patients still do require transfusions. This may be explained in part by changing demographics (more elderly patients), more patients presenting for repeat operations, and improvements in surgical and anaesthetic technology that allow more complex and invasive procedures. Cardiac surgery-with the obligate haemodilution associated with cardiopulmonary bypass - presents a great challenge in blood conservation. Erythropoietin has a role in the pharmacological therapy of cardiac surgery because cardiopulmonary bypass is associated with endogenous erythropoietin deficiency. This report discusses the mechanisms of endogenous erythropoietin production, the effect of recombinant human erythropoietin therapy, and the role of this drug in specific cardiac surgical procedures and situations.
Collapse
Affiliation(s)
- Michael N D'Ambra
- Harvard Medical School, Department of Anesthesia and Cardiac Anesthesia Group,
Massachusetts General Hospital
| |
Collapse
|
2
|
Hematopoietic Growth Factors in Transfusion Medicine. Transfus Med 2016. [DOI: 10.1002/9781119236504.ch17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
3
|
Rahman I, Hoth T, Doughty H, Bonser R. Thoraco-abdominal aneurysm repair in a Jehovah's Witness: maximising blood conservation. Perfusion 2016; 22:363-4. [DOI: 10.1177/0267659107084525] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Thoraco-abdominal aneurysm repair usually necessitates blood or blood product transfusion which is prohibited in Jehovah's Witnesses. We report the blood conservation strategy used during thoraco-abdominal aneurysm repair in a Jehovah's Witness. This included pre-operative recombinant erythropoietin, per-operative acute normovolaemic haemodilution, cell salvage, aprotinin, restricted heparinisation, left atrial-distal bypass and recombinant factor VIIa. Post-operative haemoglobin levels were maintained, but a left haemothorax necessitated re-thoracotomy on post-operative day 4. Following re-thoracotomy, Hb was 12.0 g.dL—1 and platelet count 49 × 109.L—1. Recombinant erythropoietin was recommenced. At discharge (day 12), Hb was 10.1 g.dL—1. The patient remains well at one year. A thoroughly, pre-planned multi-disciplinary blood conservation strategy can be used to undertake high-risk procedures. Perfusion (2007) 22, 363—364.
Collapse
Affiliation(s)
- I.A. Rahman
- Departments of Cardiothoracic Surgery, University Hospital Birmingham NHS Trust, Birmingham, UK
| | - T. Hoth
- Anaesthesia, University Hospital Birmingham NHS Trust, Birmingham, UK
| | - H. Doughty
- Transfusion Medicine, University Hospital Birmingham NHS Trust, Birmingham, UK
| | - R.S. Bonser
- Departments of Cardiothoracic Surgery, University Hospital Birmingham NHS Trust, Birmingham, UK,
| |
Collapse
|
4
|
Weltert L, Rondinelli B, Bello R, Falco M, Bellisario A, Maselli D, Turani F, De Paulis R, Pierelli L. A single dose of erythropoietin reduces perioperative transfusions in cardiac surgery: results of a prospective single-blind randomized controlled trial. Transfusion 2015; 55:1644-54. [DOI: 10.1111/trf.13027] [Citation(s) in RCA: 73] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2014] [Revised: 12/21/2014] [Accepted: 12/23/2014] [Indexed: 12/21/2022]
Affiliation(s)
| | | | - Ricardo Bello
- Montefiore-Einstein Heart Center; Albert Einstein College of Medicine; Bronx New York
| | - Mauro Falco
- Anaesthesiology Department; European Hospital
| | | | | | | | | | - Luca Pierelli
- Transfusion Medicine Department; San Camillo-Forlanini Hospital; Rome Italy
- Department of Experimental Medicine; Sapienza University; Rome Italy
| |
Collapse
|
5
|
Hematopoietic Growth Factors in Transfusion Medicine. Transfus Med 2011. [DOI: 10.1002/9781444398748.ch17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
6
|
Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, Cigarroa JE, Disesa VJ, Hiratzka LF, Hutter AM, Jessen ME, Keeley EC, Lahey SJ, Lange RA, London MJ, Mack MJ, Patel MR, Puskas JD, Sabik JF, Selnes O, Shahian DM, Trost JC, Winniford MD. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 58:e123-210. [PMID: 22070836 DOI: 10.1016/j.jacc.2011.08.009] [Citation(s) in RCA: 576] [Impact Index Per Article: 44.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
7
|
Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, Cigarroa JE, Disesa VJ, Hiratzka LF, Hutter AM, Jessen ME, Keeley EC, Lahey SJ, Lange RA, London MJ, Mack MJ, Patel MR, Puskas JD, Sabik JF, Selnes O, Shahian DM, Trost JC, Winniford MD, Winniford MD. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:e652-735. [PMID: 22064599 DOI: 10.1161/cir.0b013e31823c074e] [Citation(s) in RCA: 390] [Impact Index Per Article: 30.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
8
|
Chaney MA, Jellish WS, Leonetti JP. Perioperative Management of a Jehovah's Witness Presenting for Skull Base Surgery. Skull Base Surg 2011; 6:133-6. [PMID: 17170989 PMCID: PMC1656579 DOI: 10.1055/s-2008-1058906] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
A 22-year-old, otherwise healthy, female Jehovah's Witness underwent resection of a midline skull base chondrosarcoma which had been detected after a work-up for headache and diplopia. After bilateral maxillectomies, ethmoidectomies, and a sphenoidectomy, the patient's chondrosarcoma was resected. Despite proper anesthetic management and meticulous hemostasis, significant intraoperative blood loss occurred. The initial postoperative hemoglobin level was 2.3 gm/dL. The clinical concerns pertaining to the perioperative management of the Jehovah's Witness are discussed along with the patient's course and management.
Collapse
|
9
|
Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, Song HK, Clough ER, Shore-Lesserson LJ, Goodnough LT, Mazer CD, Shander A, Stafford-Smith M, Waters J, Baker RA, Dickinson TA, FitzGerald DJ, Likosky DS, Shann KG. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91:944-82. [PMID: 21353044 DOI: 10.1016/j.athoracsur.2010.11.078] [Citation(s) in RCA: 874] [Impact Index Per Article: 67.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/17/2010] [Revised: 11/20/2010] [Accepted: 11/29/2010] [Indexed: 12/16/2022]
Abstract
BACKGROUND Practice guidelines reflect published literature. Because of the ever changing literature base, it is necessary to update and revise guideline recommendations from time to time. The Society of Thoracic Surgeons recommends review and possible update of previously published guidelines at least every three years. This summary is an update of the blood conservation guideline published in 2007. METHODS The search methods used in the current version differ compared to the previously published guideline. Literature searches were conducted using standardized MeSH terms from the National Library of Medicine PUBMED database list of search terms. The following terms comprised the standard baseline search terms for all topics and were connected with the logical 'OR' connector--Extracorporeal circulation (MeSH number E04.292), cardiovascular surgical procedures (MeSH number E04.100), and vascular diseases (MeSH number C14.907). Use of these broad search terms allowed specific topics to be added to the search with the logical 'AND' connector. RESULTS In this 2011 guideline update, areas of major revision include: 1) management of dual anti-platelet therapy before operation, 2) use of drugs that augment red blood cell volume or limit blood loss, 3) use of blood derivatives including fresh frozen plasma, Factor XIII, leukoreduced red blood cells, platelet plasmapheresis, recombinant Factor VII, antithrombin III, and Factor IX concentrates, 4) changes in management of blood salvage, 5) use of minimally invasive procedures to limit perioperative bleeding and blood transfusion, 6) recommendations for blood conservation related to extracorporeal membrane oxygenation and cardiopulmonary perfusion, 7) use of topical hemostatic agents, and 8) new insights into the value of team interventions in blood management. CONCLUSIONS Much has changed since the previously published 2007 STS blood management guidelines and this document contains new and revised recommendations.
Collapse
|
10
|
Okamura Y, Takeuchi Y, Gomi A, Torii S, Mori H, Yokoyama S. Effect of erythropoietin therapy in cardiac surgery using autologous blood transfusion. Int J Angiol 2011. [DOI: 10.1007/bf02651546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
11
|
McCullough J, Kahn J, Adamson J, Anderlini P, Benjamin R, Confer D, Eapen M, Hirsch B, Kuter D, Lazarus E, Pamphilon D, Stroncek D, Sugarman J, Wilson R. Hematopoietic growth factors-use in normal blood and stem cell donors: clinical and ethical issues. Transfusion 2008; 48:2008-25. [DOI: 10.1111/j.1537-2995.2008.01788.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Ferraris VA, Ferraris SP, Saha SP, Hessel EA, Haan CK, Royston BD, Bridges CR, Higgins RSD, Despotis G, Brown JR, Spiess BD, Shore-Lesserson L, Stafford-Smith M, Mazer CD, Bennett-Guerrero E, Hill SE, Body S. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 2007; 83:S27-86. [PMID: 17462454 DOI: 10.1016/j.athoracsur.2007.02.099] [Citation(s) in RCA: 610] [Impact Index Per Article: 35.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/12/2006] [Revised: 01/21/2007] [Accepted: 02/08/2007] [Indexed: 01/24/2023]
Abstract
BACKGROUND A minority of patients having cardiac procedures (15% to 20%) consume more than 80% of the blood products transfused at operation. Blood must be viewed as a scarce resource that carries risks and benefits. A careful review of available evidence can provide guidelines to allocate this valuable resource and improve patient outcomes. METHODS We reviewed all available published evidence related to blood conservation during cardiac operations, including randomized controlled trials, published observational information, and case reports. Conventional methods identified the level of evidence available for each of the blood conservation interventions. After considering the level of evidence, recommendations were made regarding each intervention using the American Heart Association/American College of Cardiology classification scheme. RESULTS Review of published reports identified a high-risk profile associated with increased postoperative blood transfusion. Six variables stand out as important indicators of risk: (1) advanced age, (2) low preoperative red blood cell volume (preoperative anemia or small body size), (3) preoperative antiplatelet or antithrombotic drugs, (4) reoperative or complex procedures, (5) emergency operations, and (6) noncardiac patient comorbidities. Careful review revealed preoperative and perioperative interventions that are likely to reduce bleeding and postoperative blood transfusion. Preoperative interventions that are likely to reduce blood transfusion include identification of high-risk patients who should receive all available preoperative and perioperative blood conservation interventions and limitation of antithrombotic drugs. Perioperative blood conservation interventions include use of antifibrinolytic drugs, selective use of off-pump coronary artery bypass graft surgery, routine use of a cell-saving device, and implementation of appropriate transfusion indications. An important intervention is application of a multimodality blood conservation program that is institution based, accepted by all health care providers, and that involves well thought out transfusion algorithms to guide transfusion decisions. CONCLUSIONS Based on available evidence, institution-specific protocols should screen for high-risk patients, as blood conservation interventions are likely to be most productive for this high-risk subset. Available evidence-based blood conservation techniques include (1) drugs that increase preoperative blood volume (eg, erythropoietin) or decrease postoperative bleeding (eg, antifibrinolytics), (2) devices that conserve blood (eg, intraoperative blood salvage and blood sparing interventions), (3) interventions that protect the patient's own blood from the stress of operation (eg, autologous predonation and normovolemic hemodilution), (4) consensus, institution-specific blood transfusion algorithms supplemented with point-of-care testing, and most importantly, (5) a multimodality approach to blood conservation combining all of the above.
Collapse
|
13
|
Larson B, Bremme K, Clyne N, Nordström L. Preoperative treatment of anemic women with epoetin beta. Acta Obstet Gynecol Scand 2003. [DOI: 10.1034/j.1600-0412.2001.080006559.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
14
|
Beholz S, Liu J, Thoelke R, Spiess C, Konertz W. Use of desmopressin and erythropoietin in an anaemic Jehovah's Witness patient with severely impaired coagulation capacity undergoing stentless aortic valve replacement. Perfusion 2001; 16:485-9. [PMID: 11761088 DOI: 10.1177/026765910101600608] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Cardiac surgery in Jehovah's Witness patients remains a challenge in the presence of concomitant congenital or acquired coagulation disorders and anaemia. We report a case of a 66-year-old female Jehovah's Witness suffering from severe calcified aortic valve stenosis requiring aortic valve replacement. The anaemic patient suffered from concomitant platelet dysfunction and deficiency of factors V and VII due to gammopathy of immunoglobulin G. The patient was preoperatively treated with recombinant erythropoietin in combination with folic acid and iron, which resulted in an increase of the haematocrit from 0.335 to 0.416 after 22 days of treatment. Haemostasis was improved by high dose aprotinin and additional desmopressin, which could be demonstrated to be effective by a preoperative test. The patients intra- and postoperative course was uneventful, her total chest tube loss was 130 ml, and she was able to be discharged without the need of any blood transfusions. The beneficial properties of erythropoietin and desmopressin in Jehovah's Witness patients are discussed.
Collapse
Affiliation(s)
- S Beholz
- Department of Cardiovascular Surgery, University Clinic Charité, Humboldt University Berlin, Germany.
| | | | | | | | | |
Collapse
|
15
|
Alexi-Meskishvili V, Ovroutski S, Dähnert I, Fischer T. Correction of cor triatriatum sinistrum in a Jehovah's Witness infant. Eur J Cardiothorac Surg 2000; 18:724-6. [PMID: 11113683 DOI: 10.1016/s1010-7940(00)00574-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
A cor triatriatum sinistrum was successfully treated by operation in a 14-week-old infant of a Jehovah's Witness family. The child was pretreated with erythropoietin until a hemoglobin level of 14 g/dl was obtained. There was no cardiac catheterization before the operation. The operation was performed with cardiopulmonary bypass. No blood products were transfused and the hemoglobin level after performing modified ultrafiltration was 11.5 g/dl. The infant was extubated on the same day and discharged from our institution on the eighth day after surgery. Two years after surgery the child is in sinus rhythm and is developing well.
Collapse
Affiliation(s)
- V Alexi-Meskishvili
- Department of Cardiovascular and Thoracic Surgery and Department of Congenital Heart Disease, Augustenburger Platz 1, 13353, Berlin, Germany.
| | | | | | | |
Collapse
|
16
|
Braga M, Gianotti L, Gentilini O, Vignali A, Corizia L, Carlo V. Erythropoiesis after Therapy with Recombinant Human Erythropoietin: A Dose-Response Study in Anemic Cancer Surgery Patients. Vox Sang 1999. [DOI: 10.1046/j.1423-0410.1999.7610038.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
17
|
Abstract
Recombinant human erythropoietin has been approved for use in patients undergoing autologous donation in Japan, Europe, and Canada since 1993, 1994, and 1996, respectively, and for perisurgical adjuvant therapy without autologous donation in Canada and the United States since 1996. Early clinical trials of erythropoietin therapy in the setting of autologous donation have provided important information regarding clinical safety, erythropoietin dose, and erythropoietic response. Later trials of perisurgical erythropoietin therapy without autologous donation provided data on efficacy (reduced allogeneic blood exposure) that led to approval of erythropoietin in patients undergoing surgery. However, the erythropoietin doses (300 U/kg subcutaneous x14 days) used in these trials, and their subsequent inclusion in labeling for the use of this product, are costly and tedious to administer. A recent study reported that a weekly regimen of erythropoietin (600 U/kg) for 4 weeks is less costly but just as effective at reducing allogeneic blood exposure in elective orthopaedic surgery. The most cost effective regimen that has been shown to minimize allogeneic exposure is preoperative erythropoietin therapy (600 U/kg subcutaneous weekly x2 and 300 U/kg subcutaneous on day of surgery) coupled with acute normovolemic hemodilution in patients undergoing radical retropubic prostatectomy. A similar regimen of erythropoietin therapy in patients undergoing coronary artery bypass grafting (2500 U/kg subcutaneous in divided doses for 2 weeks preoperatively) coupled with hemodilution also was effective. Low dose erythropoietin therapy coupled with acute normovolemic hemodilution ultimately may be shown to be cost equivalent to the predonation of three autologous blood units before elective surgery.
Collapse
Affiliation(s)
- L T Goodnough
- Division of Lab Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
| | | |
Collapse
|
18
|
D'Ambra MN, Gray RJ, Hillman R, Jones JW, Kim HC, Rawitscher R, Schnaper H, Szymanski I, Vlahakes GJ, Kaplan D, Lynch KE, Guilfoyle M, Abels RI. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg 1997; 64:1686-93. [PMID: 9436556 DOI: 10.1016/s0003-4975(97)00839-4] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND Patients having a cardiac operation frequently require allogeneic blood transfusions despite surgical blood-conservation techniques. Recombinant human erythropoietin (Epoetin alfa) may augment this conservation by stimulating erythropoiesis. The safety and efficacy of perioperative use of Epoetin alfa to reduce the need of allogeneic transfusion was studied. METHODS A multicenter double-blind, placebo-controlled, parallel-group study involved 182 patients having coronary artery bypass grafting and randomized to receive Epoetin alfa (300 or 150 IU/kg) or placebo subcutaneously for 5 days before, on the day of, and for 2 days after operation. RESULTS Perioperative Epoetin alfa resulted in greater increases in baseline to preoperative hemoglobin levels and hematocrit (300 IU/kg) and in presurgery to postsurgical day 1 reticulocyte counts versus placebo (p < or = 0.05). However, there was no significant difference in transfusion requirements. Incidences of adverse events were similar in all study groups. CONCLUSIONS Lower incidences of allogeneic blood exposure were observed in both Epoetin alfa-treated groups; however, the differences between all treatment groups were not significant. This was probably due to the relatively short 5-day preoperative course of Epoetin alfa therapy. There were no significant differences between the three groups relative to safety. Epoetin alfa was well tolerated in this population.
Collapse
Affiliation(s)
- M N D'Ambra
- Cardiac Anesthesia Group, Massachusetts General Hospital, Boston 02114-2696, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
Hematopoietic growth factors, glycoproteins that stimulate self-renewal, differentiation, and proliferation of responsive hematopoietic cells, promise to revolutionize transfusion medicine. Recombinant DNA technology has made several of these cytokines available at pharmacologic doses, and new candidate agents for clinical application appear regularly. Growth factors prescribed for patients have already reduced the requirement for red blood cell and granulocyte transfusions in selected clinical circumstances. A lineage-specific thrombopoietin will likely limit the need for platelet transfusions. Hematopoietic cytokine injections have also been used to increase the number of red blood cells, granulocytes and circulating primitive progenitor cells in blood donors. Cytokine-stimulated peripheral blood progenitor cell infusions have complemented and, in some instances, replaced bone marrow for adjunctive cancer chemotherapy and for bone marrow transplantation. Finally, synergistic combinations of cytokines can effect ex vivo expansion of lymphocytes and of progenitor cells to provide novel blood components. Hematopoietic growth factors are still expensive and their long-term effects remain to be determined. However, as the biologic activities of cytokines and the physiology of hematopoietic progenitor cells become better understood, the clinical application of novel cellular components may redefine the concept of blood transfusion.
Collapse
Affiliation(s)
- Y M Miller
- Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Md., USA
| | | |
Collapse
|
20
|
Abstract
In a double-blind, multicenter study, 200 patients who could not or would not donate autologous blood before major orthopedic surgery requiring transfusion of at least 2 units of whole blood were randomized to receive placebo (n = 69) or recombinant human erythropoietin (Epoetin alfa) in daily doses of 300 U/kg (n = 60) or 100 U/kg (n = 71) for 15 consecutive days, starting 10 days before surgery and extending through the fourth postoperative day. Of these, 185 patients who received active medication or placebo and underwent surgery were qualified for evaluation of efficacy (n = 67, n = 54, and n = 64, respectively). All patients received concomitant oral iron supplementation. Compared with placebo-treated patients, a significantly lower proportion of patients who received either dose of Epoetin alfa required allogeneic blood transfusions (54% for placebo, 17% for 300 U/kg, 25% for 100 U/kg; p < 0.01), as well as fewer mean units of blood (1.42 units for placebo, 0.37 units for 300 U/kg, 0.58 units for 100 U/kg; p < 0.01). The differences between the Epoetin alfa treatment groups were not statistically significant. On the basis of these results, perioperative Epoetin alfa therapy in conjunction with iron supplementation may have a place as an adjunct to elective orthopedic surgery, particularly if dosing regimens less frequent than once daily can be established.
Collapse
Affiliation(s)
- P Faris
- Kendrick Memorial Hospital Center for Hip and Knee Surgery, Mooresville, Indiana 46158-1788, USA
| |
Collapse
|
21
|
Chikada M, Furuse A, Kotsuka Y, Yagyu K. Open-heart surgery in Jehovah's Witness patients. CARDIOVASCULAR SURGERY (LONDON, ENGLAND) 1996; 4:311-4. [PMID: 8782926 DOI: 10.1016/0967-2109(95)00135-2] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Open-heart surgery has been performed since 1975 on 25 patients who are Jehovah's Witnesses by religion. The patients' ages ranged from 6-60 years, and their body weights from 18-51 kg. Surgical procedures included correction of congenital heart disease in 14 patients and valve repair or replacement in 11. Six procedures were reoperations. The lowest mean haematocrits, during perfusion and the postoperative period, were 22.7% (range 15.0-31.0%) and 27% (range 16.0-36.0%), respectively. Twenty-four patients survived and are alive and well. One patient died of low output failure before discharge. The blood return system reduced blood loss. Five of the patients who underwent cardiac surgery received recombinant erythropoietin before and after surgery, leading to higher postoperative haematocrits. In one patient, a haematocrit which fell to 16.9% after surgery was raised to 27% by administration of erythropoietin, without blood transfusion. In two recent cases, high doses of aprotinin were used during surgery, resulting in better haemostasis after cardiopulmonary bypass.
Collapse
Affiliation(s)
- M Chikada
- Department of Cardiothoracic Surgery, University of Tokyo, Japan
| | | | | | | |
Collapse
|
22
|
Faris PM, Ritter MA, Abels RI. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. The American Erythropoietin Study Group. J Bone Joint Surg Am 1996; 78:62-72. [PMID: 8550681 DOI: 10.2106/00004623-199601000-00009] [Citation(s) in RCA: 171] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Two hundred patients who were scheduled for a major elective orthopaedic operation were enrolled in a prospective study and were randomly assigned to one of three treatment groups. Group 1 consisted of sixty patients who received recombinant human erythropoietin, 300 international units per kilogram of body weight per day; Group 2, seventy-one patients who received recombinant human erythropoietin, 100 international units per kilogram of body weight per day; and Group 3, sixty-nine patients who received a placebo. A total of fifteen doses was given subcutaneously, beginning ten days before the operation and extending through the fourth postoperative day. Patients who declined or were unable to donate autologous blood preoperatively were included in the study and were maintained on iron supplementation orally. The decision to transfuse red blood cells depended on the physician, however, physicians were encouraged not to do so if the hematocrit was more than 0.27 (27 per cent), unless the clinical symptoms warranted it. Of the 185 patients who were evaluable with regard to efficacy, significantly fewer patients received homologous red-blood-cell transfusions in Groups 1 and 2 (17 per cent [nine] and 25 per cent [sixteen], respectively) than in Group 3 (54 per cent [thirty-six]) (p < 0.001). When the patients were stratified into two groups on the basis of the pre-treatment hemoglobin level (more than 100 to 130 grams per liter or more than 130 grams per liter), we found that patients who had received a placebo and had a baseline hemoglobin level of more than 100 to 130 grams per liter were at significantly higher risk for transfusion (78 per cent [twenty-one]) than those who had received a placebo and had a baseline level of more than 130 grams per liter (36 per cent [fourteen]). For patients who had a baseline hemoglobin level of more than 100 to 130 grams per liter, the higher dose of recombinant human erythropoietin appeared somewhat more effective than the lower dose, with 14 per cent (three) of the patients in Group 1 and 39 per cent (nine) in Group 2 needing a transfusion; however, the difference was not significant (p = 0.09). For patients who had a baseline hemoglobin level of more than 130 grams per liter, the two doses of recombinant human erythropoietin produced similar results, with 14 per cent (four) of the patients in Group 1 and 11 per cent (four) in Group 2 needing a transfusion; this was in contrast to a rate of transfusion of 36 per cent (fourteen) in Group 3 (the patients who received the placebo) (p = 0.03). The recombinant human erythropoietin was generally well tolerated, although one patient, who did not have a history of hypertension, had an increase in blood pressure, from a baseline level of 142/78 millimeters of mercury (18.93/10.40 kilopascals) to a level of 220/100 millimeters of mercury (29.33/13.33 kilopascals), after ten days of treatment with the higher dose. These data suggest that recombinant human erythropoietin, administered before and after major orthopaedic operations, can minimize the need for homologous red-blood-cell transfusion.
Collapse
Affiliation(s)
- P M Faris
- Center for Hip and Knee Surgery, Mooresville, Indiana 46158, USA
| | | | | |
Collapse
|
23
|
Braga M, Gianotti L, Vignali A, Gentilini O, Servida P, Bordignon C, Di Carlo V. Evaluation of recombinant human erythropoietin to facilitate autologous blood donation before surgery in anaemic patients with cancer of the gastrointestinal tract. Br J Surg 1995; 82:1637-40. [PMID: 8548226 DOI: 10.1002/bjs.1800821216] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The aim of this study was to determine whether the preoperative administration of recombinant human erythropoietin (rHuEPO) could increase the rate of autologous blood donation and reduce the perioperative need for homologous blood in anaemic patients with cancer. Twenty-two anaemic (haematocrit less than 34 per cent), iron-deficient (iron less than 700 micrograms/l) patients, with gastric or colorectal cancer scheduled for elective surgery, were allocated randomly to two groups. The first (n = 11) received iron saccharate 200 mg/day intravenously for 12 consecutive days. The second (n = 11) received rHuEPO subcutaneously (300 units/kg as first administration, and 100 units/kg 4, 8 and 12 days later) with supplemental iron. On days 4, 8 and 12, if the haematocrit was greater than 34 per cent, patients donated one unit (350 ml) of autologous blood. In the iron group the mean haematocrit did not change from admission (31 per cent) to day 12 of treatment (31 per cent), and no patient could donate autologous blood. In the rHuEPO group, eight patients donated two units of autologous blood and three donated one unit. Four patients in the iron group received perioperative transfusion of homologous blood compared with none in the rHuEPO group. Administration of rHuEPO facilitated the donation of autologous blood and reduced perioperative homologous blood transfusion in anaemic patients with cancer.
Collapse
Affiliation(s)
- M Braga
- Department of Surgery, Scientific Institute San Raffaele Hospital, University of Milan, Italy
| | | | | | | | | | | | | |
Collapse
|
24
|
Abstract
Recombinant human growth factors are expected to have a significant impact on the use of allogeneic blood components. For example, subsequent to the approval of recombinant human erythropoietin, blood transfusions in renal dialysis patients declined substantially. Likewise, myeloid growth factors have reduced infections and hospital stay by promoting hematologic recovery after high dose ablative chemotherapy. The high costs of these agents mandate that their use be limited to settings where they are clinically indicated. The use of growth factors may be monitored at medical centers by hospital transfusion committees. This chapter reviews the emerging clinical guidelines for the use of hematopoietic growth factors.
Collapse
Affiliation(s)
- L T Goodnough
- Washington University School of Medicine, St Louis, MO 63110, USA
| | | |
Collapse
|
25
|
|
26
|
Janssens M, Lamy M. [Role of recombinant erythropoietin during the preoperative period]. ANNALES FRANCAISES D'ANESTHESIE ET DE REANIMATION 1995; 14 Suppl 1:98-106. [PMID: 7486323 DOI: 10.1016/s0750-7658(05)81808-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
- M Janssens
- Département d'Anesthésiologie, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman, Belgique
| | | |
Collapse
|
27
|
Goodnough LT. Clinical Application of Recombinant Erythropoietin in the Perioperative Period. Hematol Oncol Clin North Am 1994. [DOI: 10.1016/s0889-8588(18)30144-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
28
|
Kantrowitz AB, Spallone A, Taylor W, Chi TL, Strack M, Feghali JG. Erythropoietin-augmented isovolemic hemodilution in skull-base surgery. Case report. J Neurosurg 1994; 80:740-4. [PMID: 8151356 DOI: 10.3171/jns.1994.80.4.0740] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Human erythropoietin in concert with intraoperative hemodilution, tumor embolization, and surgical staging was used to manage a red blood cell mass in an anemic Jehovah's Witness patient with a hypervascular meningioma. Erythropoietin (3000 U thrice weekly) and oral iron (1300 mg daily) were given for 1 month prior to surgery, raising the hemoglobin level from 11.8 to 14.1 gm/100 ml. A posterior fossa craniectomy combined with a temporal craniectomy was then performed so that partial petrosectomy, section of the transverse sinus, incision of the tentorium, and exposure of the lesion could be carried out. The first stage of the surgery was terminated immediately prior to tumor mobilization. Isovolemic hemodilution was initiated just before the skin incision. Postoperatively, the hemoglobin concentration dropped to 11.5 gm/100 ml. The erythropoietin dose was doubled and administration of oral iron continued, leading to a hemoglobin level of 14.0 gm/100 ml at 1 month after the first operation. The tumor was embolized using superselective catheterization. The next day, at the second stage of the surgery, the tumor was extirpated, again employing isovolemic hemodilution. By the 4th postoperative day, the hemoglobin level had dropped to 9.4 gm/100 ml. The patient made an uncomplicated recovery. Erythropoietin therapy contributed substantially to the successful outcome of this case. Since erythropoietin has the potential to augment all other forms of autologous banking, its role in elective neurosurgery may become increasingly important in an era of heightened concern about heterologous transfusion.
Collapse
Affiliation(s)
- A B Kantrowitz
- New York Center for Cranial Base Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx
| | | | | | | | | | | |
Collapse
|
29
|
Litvan H, Santacana E, Casas JI, Aris A, Villar Landeira JM. Aprotinin therapy to reduce blood loss in Jehovah's Witnesses. Can J Anaesth 1994; 41:77-8. [PMID: 7509265 DOI: 10.1007/bf03009674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
|
30
|
|
31
|
Schiff SJ, Weinstein SL. Use of recombinant human erythropoietin to avoid blood transfusion in a Jehovah's Witness requiring hemispherectomy. Case report. J Neurosurg 1993; 79:600-2. [PMID: 8410232 DOI: 10.3171/jns.1993.79.4.0600] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
The use of perioperative human recombinant erythropoietin is described in a Jehovah's Witness patient. Despite significant anemia, the child's hematocrit was sufficiently increased by the use of erythropoietin so that a two-stage hemispherectomy could be performed without blood transfusion.
Collapse
Affiliation(s)
- S J Schiff
- Department of Neurosurgery, Children's National Medical Center, Washington, D.C
| | | |
Collapse
|
32
|
Abstract
Erythropoietin is the primary growth factor for red blood cells. A glycoprotein hormone synthesized by the kidneys, erythropoietin serves to increase red blood cell production in response to tissue hypoxia. It exerts its effect by increasing the numbers of erythroid progenitor cells in the bone marrow, and by increasing the rate at which their development is accomplished. With the introduction of recombinant erythropoietin in 1987, an important pharmacological agent became available for the manipulation of erythropoiesis. While used primarily for the treatment of the anemia of renal failure, recombinant erythropoietin has also shown usefulness in treating other types of anemias in which the endogenous erythropoietin response is insufficient. Perioperative use of the drug grew as a natural extension of this, and erythropoietin has been applied to correct preoperative anemia, augment autologous blood donation, and improve postoperative red cell recovery. Analysis of these perioperative clinical studies reveals success in these areas, but it also reveals that closer attention to the physiology of the natural response, and to the pharmacology of the recombinant product, might significantly improve results. Such an improvement in efficacy is both desirable and necessary when use of the drug is viewed in the setting of today's changing health care environment. By optimizing dosing schedules and targeting the drug to those most at risk for red cell transfusion, recombinant erythropoietin will likely become an important tool in efforts to achieve the elusive goal of bloodless cardiac surgery.
Collapse
Affiliation(s)
- R E Helm
- Department of Cardiothoracic Surgery, New York Hospital-Cornell Medical Center, NY 10021
| | | | | | | | | | | |
Collapse
|
33
|
Westaby S, Parry AJ, Lamont P, Grebenik C. Massive descending thoracic aneurysm in a Jehovah's witness: treatment by thromboexclusion. Ann Thorac Surg 1993; 55:1233-5. [PMID: 8494437 DOI: 10.1016/0003-4975(93)90040-o] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The thromboexclusion technique was used to treat a massive thoracic aneurysm in a Jehovah's witness. Preoperative erythropoietin therapy was used. At operation a Hemashield graft was used to bypass the aneurysm before the mouth was stapled closed. The hemoglobin level fell from 13.5 to 10.6 g/dL.
Collapse
Affiliation(s)
- S Westaby
- Department of Cardiac Surgery, Oxford Heart Centre, England
| | | | | | | |
Collapse
|
34
|
Neustein SM, Bronheim D, Galla J, Litwak R, Rand J, Scott BH, Hartman AR, Poppers PJ, Bert AA, Feng WC. Case 1--1993. The role of erythropoietin in Jehovah's Witnesses requiring cardiac surgery. J Cardiothorac Vasc Anesth 1993; 7:95-102. [PMID: 8431584 DOI: 10.1016/1053-0770(93)90127-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
- S M Neustein
- Department of Anesthesiology, Mount Sinai Medical Center, New York, NY 10029
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Estioko MR, Litwak RS, Rand JH. Reoperation, emergency and urgent open cardiac surgery in Jehovah's Witnesses. Chest 1992; 102:50-3. [PMID: 1623795 DOI: 10.1378/chest.102.1.50] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Progressive advances in perfusion technology and perioperative supportive management have made it possible for members of the Jehovah's Witnesses religious group to undergo open cardiac operations with remarkable safety. However, hospital mortality remains high in (1) patients requiring reoperation (in whom both technical and bleeding problems tend to be more frequent) and (2) patients with significantly compromised cardiac performance requiring urgent or emergency operation. Employing a number of perioperative measures designed to minimize blood loss and maintain hematocrit levels (including use of the recently available recombinant human erythropoietin in two patients whose cases are reported herein), 13 reoperations and five urgent or emergency operations were performed. The one death in the entire series occurred in a patient (reoperation group) who died of a cerebrovascular accident of presumed embolic etiology, having undergone combined debridement of a stenotic heavily calcified aortic valve and a second coronary artery revascularization procedure. None of the patients required surgical exploration for bleeding. We suggest that currently available methodology permits Jehovah's Witnesses to undergo reoperation, emergency surgery, or urgent open cardiac operation at a level of risk not dissimilar to that seen in patients who permit use of homologous blood and products in their treatment.
Collapse
Affiliation(s)
- M R Estioko
- Division of Cardiothoracic Surgery, Mount Sinai Medical Center, New York
| | | | | |
Collapse
|
36
|
|